Takeaway

• Gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety in patients with biliary tract cancer.

Why this matters

• Outcomes for these patients remain poor.
• These findings support the ongoing phase 3, TOPAZ-1 study (NCT03875235) of gemcitabine and cisplatin plus durvalumab as first-line treatment in patients with advanced biliary...